Talimogene laherparepvec: overview, combination therapy and current practices.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2016-12-01 Epub Date: 2016-09-15 DOI:10.2217/mmt-2016-0021

Cristina O'Donoghue, Matthew P Doepker, Jonathan S Zager

引用次数: 4

Abstract

Talimogene laherparepvec (T-VEC, Imlygic^®, Amgen, CA, USA) is an oncolytic herpes simplex type 1 virus used as intralesional therapy for unresectable metastatic melanoma in a cutaneous, subcutaneous or nodal location. Talimogene laherparepvec selectively replicates within and lyses tumor cells while producing granulocyte macrophage colony-stimulating factor, which may promote an immune mediated antitumor response. The US FDA approved T-VEC in late 2015 following Phase I-III trials that demonstrated safety and efficacy. Future directions for T-VEC include combination therapies with other systemic immunotherapies such as anti-CTLA-4 antibody and anti-PD-1 drugs. Current National Comprehensive Cancer Network (NCCN) practice guidelines have added T-VEC as a primary treatment for stage IIIB/C and stage IVM1a melanoma patients.

Abstract Image

查看原文本刊更多论文

Talimogene laherparepvec：综述、联合治疗和当前实践。

Talimogene laherparepvec（T-VEC，Imlygic®，Amgen，CA，USA）是一种溶瘤性单纯疱疹1型病毒，用于皮肤、皮下或淋巴结部位不可切除的转移性黑色素瘤的病灶内治疗。Talimogene laherparepvec选择性地在肿瘤细胞内复制并裂解肿瘤细胞，同时产生粒细胞-巨噬细胞集落刺激因子，这可能促进免疫介导的抗肿瘤反应。美国食品药品监督管理局在I-III期试验证明安全性和有效性后，于2015年底批准了T-VEC。T-VEC的未来方向包括与其他系统免疫疗法的联合治疗，如抗CTLA-4抗体和抗PD-1药物。目前的国家癌症综合网络（NCCN）实践指南增加了T-VEC作为IIIB/C期和IVM1a期黑色素瘤患者的主要治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.